menu
    • menu
    [{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Bell Potter Securities"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGF2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGF2","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pentosan polysulfate

    Menu

    Pentosan polysulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Australia's Paradigm Biopharmaceuticals Says Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modificati...

                            Details : Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. Clinical study has demonstrated that iPPS may slow the progression of osteoarthritis of the knee.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2023

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial

                            Details : Pentosan Polysulfate Sodium (under the name Zilosul®) is used to treat osteoarthritis. iPPS impacted multiple biomarkers measured in the synovial fluid. Reductions in nerve growth factor (NGF) indicate iPPS mechanisms related to pain reduction.

                            Brand Name : Zilosul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases

                            Details : Three of the four subjects included in Paradigm's open-label phase 2 trial of pentosan polysulfate sodium (PPS) in MPS-I have completed the 48-week study, with a 6-month treatment extension available.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program

                            Details : Zilosul (pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs).

                            Brand Name : Zilosul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S

                            Details : The purpose of the study is to measure the change in pain and function with subcutaneous injections of Zilosul (Pentosan Polysulfate Sodium) compared with subcutaneous injections of placebo in participants with kOA pain.

                            Brand Name : Zilosul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 17, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals Receives US FDA Feedback on IND Application for PPS in Knee OA

                            Details : In parallel, Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia. Additional sites may be added in order to ensure completion of this pivotal study, within the planned commercialisation timelines.

                            Brand Name : Zilosul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2021

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals has Clear Path Towards Zilosul® OA Phase 3 Clinical Trial and Product Registratio...

                            Details : Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for Zilosul®...

                            Brand Name : Zilosul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2020

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Bell Potter Securities

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol

                            Details : Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 20, 2020

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Bell Potter Securities

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth